Is 3B BlackBio Dx the Best Stock in Its Sector? A Look at the Numbers
- October 22, 2026
- Posted by: Harsh Piplani
- Category: Market
3B BlackBio Dx CMP Rs 1,319 (22 Oct 2026). Market cap Rs 1,130 Cr. ROE 15.46%. P/E 22.17x versus Industry P/E 81.48x.
Quick Answer
3B BlackBio Dx is one of the names investors compare when screening the Molecular Diagnostics sector. Whether it is the best stock in its sector depends on whether an investor prioritises return ratios, valuation or balance sheet strength. This article sets it against two named peers and the sector benchmark so you can judge for yourself.
Is 3B BlackBio Dx the best stock in its sector? The stock trades on the NSE at Rs 1,319 as of 22 October 2026, within its 52-week range of Rs 1,085.00 to Rs 1,740.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About 3B BlackBio Dx
3B BlackBio Dx Ltd manufactures and exports PCR based molecular diagnostic kits, PCR enzymes and reagents, and agrochemical based products, and company information says it was formerly known as Kilpest India Ltd. Company information describes two businesses, molecular diagnostics and agrochemicals, with diagnostics as the primary focus. The diagnostics arm designs, develops, manufactures and commercialises qPCR assays, rapid diagnostic tests, NGS based kits, digital PCR assays and nucleic acid extraction solutions across infectious diseases, oncology, genetics and antimicrobial resistance, and the registered office and factory are at Govindpura, Bhopal. At a market capitalisation of Rs 1,130 Cr, it is tracked as part of the Molecular Diagnostics sector on Univest.
Is 3B BlackBio Dx the Best Stock in Its Sector?
3B BlackBio Dx makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, backed by its return on equity. 3B BlackBio Dx’s 22.17x P/E is below the 81.48x Industry P/E and Thyrocare Technologies at 44.76x, though above Dhanuka Agritech at 14.34x, while its 15.46% ROE is lower than Thyrocare Technologies at 27.85% and Dhanuka Agritech at 17.08%, and its debt to equity ratio of 0.00 is below Thyrocare Technologies at 0.09 and Dhanuka Agritech at 0.02.
| Metric | 3B BlackBio Dx |
|---|---|
| CMP (NSE) | Rs 1,318.90 |
| 52-Week High / Low | Rs 1,740.00 / Rs 1,085.00 |
| Market Cap | Rs 1,130 Cr |
| P/E (TTM) vs Industry P/E | 22.17x vs 81.48x |
| P/B | 3.54 |
| ROE | 15.46% |
| EPS (TTM) | Rs 59.37 |
| Dividend Yield | 0.38% |
| Debt to Equity | 0.00 |
Compare 3B BlackBio Dx Against Other Molecular Diagnostics Sector Stocks
How 3B BlackBio Dx Compares Against Its Molecular Diagnostics Sector Peers
The table below sets 3B BlackBio Dx against 2 other Molecular Diagnostics sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| 3B BlackBio Dx | 1,130 | 22.17 | 15.46% | 0.00 |
| Thyrocare Technologies | 7,873 | 44.76 | 27.85% | 0.09 |
| Dhanuka Agritech | 3,845 | 14.34 | 17.08% | 0.02 |
| Peer average (2 companies) | – | 29.55 | 22.46% | 0.06 |
Measured against the peer averages, 3B BlackBio Dx’s P/E is 25 percent below the 29.55x average, and its ROE is 7.00 percentage points below the 22.46% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.
What Makes 3B BlackBio Dx Worth Watching in Molecular Diagnostics
- Scale: At Rs 1,130 Cr, its market capitalisation is smaller than Thyrocare Technologies (Rs 7,873 Cr) and Dhanuka Agritech (Rs 3,845 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
- Sector drivers: Demand for molecular diagnostic kits and reagents, export orders and the mix between diagnostics and agrochemicals drive revenue and margins.
- Key risk: Diagnostics demand can swing with testing cycles and the pace of new product approvals, so volumes may not be steady. The agrochemical segment also depends on seasonal farm demand.
3B BlackBio Dx Valuation: Is It Justified?
At a P/B ratio of 3.54, the market pays about Rs 3.54 for every rupee of book value, and the EPS (TTM) of Rs 59.37 is the earnings base behind the P/E. The stock trades about 24 percent below its 52-week high and about 22 percent above its 52-week low. The dividend yield of 0.38% is a modest income component, so returns depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track 3B BlackBio Dx and other Molecular Diagnostics sector stocks.
How to Track 3B BlackBio Dx Before You Invest
Before deciding whether 3B BlackBio Dx deserves its label as the best stock in its sector for your own portfolio, compare it directly against Molecular Diagnostics sector peers using the steps below.
- Open the Univest Screener and search for 3B BlackBio Dx to view live price, valuation ratios, and peer comparisons within the Molecular Diagnostics sector.
- Compare its P/E, P/B, and ROE against other Molecular Diagnostics sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
3B BlackBio Dx gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Molecular Diagnostics depends on how much weight you give each of them and on how the business executes from here. Because the stock trades below its sector benchmark, the open question is whether earnings growth will close that gap or whether the discount is deserved. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is 3B BlackBio Dx the best stock in its sector?
Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. 3B BlackBio Dx has a 15.46% ROE and trades at 22.17x P/E against an 81.48x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 22.46% peer average and its P/E is below the 29.55x peer average. Its debt to equity ratio of 0.00 is below the 0.06 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.
What is the current share price of 3B BlackBio Dx?
Ans. 3B BlackBio Dx was trading at Rs 1,318.90 on the NSE as of 22 October 2026, and its 52-week range runs from Rs 1,085.00 to Rs 1,740.00. That leaves the share price 24 percent short of the 52-week high and 22 percent clear of the 52-week low. Its market capitalisation is Rs 1,130 Cr and its EPS (TTM) is Rs 59.37, which is the earnings figure behind the 22.17x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.
What sector does 3B BlackBio Dx belong to?
Ans. 3B BlackBio Dx is classified under the Molecular Diagnostics sector on Univest, and that group of listed companies is the reference point for the 81.48x Industry P/E used in this article. The 2 named peers compared here are Thyrocare Technologies and Dhanuka Agritech, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Molecular Diagnostics sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.
How does 3B BlackBio Dx compare to its sector peers on P/E?
Ans. 3B BlackBio Dx’s P/E of 22.17x is below the 29.55x average of the 2 named peers, with Thyrocare Technologies at 44.76x and Dhanuka Agritech at 14.34x. It also sits below the 81.48x Industry P/E, which is the benchmark for the wider Molecular Diagnostics sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 3.54 gives one more view of how the market values its book value.
What is 3B BlackBio Dx’s return on equity?
Ans. 3B BlackBio Dx reported a return on equity of 15.46%, which is below the 22.46% average of its named peers, with Thyrocare Technologies at 27.85% and Dhanuka Agritech at 17.08%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.00 against a peer average of 0.06. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.
Should I invest in 3B BlackBio Dx based on its sector position?
Ans. Sector position is only one input into an investment decision. 3B BlackBio Dx has a 15.46% ROE and a 22.17x P/E, which make it worth researching further, and its dividend yield is 0.38%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.
